Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden

Overview of attention for article published in BMC Infectious Diseases, February 2019

Altmetric Badge

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 32 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 17 publications that cite this research output.

17

The most recent citing publications are shown below. View all 17 publications that cite this research output on Dimensions.

Economic and budgetary impact evaluation of isavuconazole (Cresemba®) versus voriconazole (Vfend®) for the treatment of patients with possible invasive aspergillosis from the perspective of the Brazilian supplementary health system

Article in PLOS ONE (March 2024)

Pharmacoeconomic evaluation of isavuconazole, posaconazole, and voriconazole for the treatment of invasive mold diseases in hematological patients: initial therapy prior to pathogen differential diagnosis in China

Article in Frontiers in Public Health (December 2023)

A systematic review and meta‐analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections

Article in Mycoses (June 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.